Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

Recruiting Phase 2 Interventional Study
Endometriosis
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
21 and older
Sex
Female
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
30 (estimated)
Sponsor
Mclean Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Despite the proliferation of cannabis and cannabinoid products in recent years, little research has been done to determine the impact of these products on womens health conditions, including endometriosis. This study is designed to assess the impact of a custom-formulated, hemp-derived, full-spectrum, high-CBD product vs. placebo on clinical symptoms and biomarkers over the course of 12 weeks of t…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Subject has provided informed consent 2. Sex assigned female at birth 3. Subject is 21 or older 4. Subject is fluent in English 5. Subject endorses at least moderate levels of pain at the baseline visit 6. Subject endorses having endometriosis Exclusion Criteria: 1. Non-flu…
Contacts

Staci Gruber, PhD

617-855-2762

gruber@mclean.harvard.edu

CONTACT

Rosie Smith, M.S.

617-855-2908

rsmith@mclean.harvard.edu

CONTACT